Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of LEP-ETU in Patients Completing LEP-ETU-102A
2004-001349-14Phase 2Completed
- Sponsor
- Neopharm
- Start
- Oct 2004
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of liposomal paclitaxel in Non-hematologic malignancy, sponsored by Neopharm. Primary endpoint: Treatment continuation until disease progression or unacceptable toxicity. Started Oct 2004; status: completed.
02
Drugs
liposomal paclitaxel
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2004-001349-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001349-14.